Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | REN | P00797 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27349217 | 0.88 | FOLH1 (0.43) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL27349222 | 0.87 | NFKB1 (0.38) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL22552098 | 0.83 | CA1 (0.40) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL22579105 | 0.83 | CA1 (0.40) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL22552096 | 0.83 | CA1 (0.40) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL24529277 | 0.80 | FOLH1 (0.36) | CYP19A1FOLH1CYP1A1CTSKREN | |
| SCHEMBL28150955 | 0.80 | CYP2D6 (0.40) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL18681582 | 0.80 | CYP2D6 (0.40) | CYP19A1FOLH1CYP1A1CTSKCTSS | |
| SCHEMBL27349588 | 0.78 | CYP1A2 (0.35) | CTSKCTSSRENSCN9ACA1 | |
| SCHEMBL23314676 | 0.77 | REN (0.36) | CYP19A1FOLH1CYP1A1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | TRAWSFYNYDD THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4540227-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | ACE2, ACE, TMPRSS2 | CYP19A1 770/4885FOLH1 676/4885CYP1A1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.